Health Economics›Hepatocellular carcinoma›First-line therapy for advanced or metastatic disease

First-line therapy for advanced or metastatic disease

Hepatocellular carcinoma · 26 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Durvalumab and Tremelimumab Variant #01 Partial	—	R 131 701	28d	—	16.4 mo	2	R 263 402 PFS proxy	3
Durvalumab monotherapy Variant #01	—	R 61 460	14d	—	16.6 mo	26	R 1 597 971 PFS proxy	2
Atezolizumab and Bevacizumab Variant #01	—	R 61 241	21d	—	19.2 mo	2	R 122 482 PFS proxy	1
Sunitinib monotherapy Variant #01	—	R 33 433	42d	—	7.9 mo	2	R 49 300 PFS proxy	1
Capecitabine and Bevacizumab Variant #01	—	R 31 025	21d	~9.1 mo	—	~2	~R 62 050 PFS proxy · indirect	7
Lenvatinib monotherapy Variant #01	—	R 27 935	28d	8.0 mo	16.0 mo	2	R 55 870 PFS proxy	5
Erlotinib and Bevacizumab Variant #01	—	R 26 036	28d	~16.4 mo	~49.1 mo	~52	~R 1 353 852 PFS proxy · indirect	7
Bevacizumab monotherapy Variant #01	—	R 19 082	14d	~4.9 mo	—	~52	~R 992 271 PFS proxy · indirect	—
Doxorubicin and Sorafenib Variant #01	—	R 16 622	21d	—	13.7 mo	10	R 165 602 PFS proxy	1
Sorafenib monotherapy Variant #04	—	R 16 002	28d	3.7 mo	10.7 mo	2	R 32 005 PFS proxy	33
GemOx and Sorafenib Variant #01	—	R 13 605	14d	—	—	~2	~R 27 211 indirect	—
CapeOx and Bevacizumab Variant #01	—	R 12 911	21d	~10.3 mo	—	~12	~R 154 931 PFS proxy · indirect	4
mFOLFOX and Sorafenib Variant #01	—	R 12 860	14d	—	—	~2	~R 25 720 indirect	—
FULV Variant #29	—	R 3 601	14d	~5.6 mo	~13.1 mo	~2	~R 7 201 PFS proxy · indirect	15
GemOx Variant #01	—	R 2 937	14d	~5.0 mo	~9.0 mo	~7	~R 20 560 PFS proxy · indirect	5
CapeOx Variant #01	—	R 2 620	21d	~6.7 mo	~12.2 mo	~8	~R 20 959 PFS proxy · indirect	20
FOLFOX4 Variant #01	—	R 2 374	14d	—	6.4 mo	3	R 7 122 PFS proxy	1
Capecitabine monotherapy Variant #01	—	R 1 039	21d	~5.7 mo	~7.5 mo	~8	~R 8 309 PFS proxy · indirect	11
Doxorubicin monotherapy Variant #01	—	R 902	21d	—	6.5 mo	9	R 8 114 PFS proxy	4
Tamoxifen monotherapy Variant #01	—	R 137	28d	—	6.0 mo	26	R 3 553 PFS proxy	—
Best supportive care Partial	—	—	—	—	16.0 mo	—	—	3
Tislelizumab monotherapy Variant #01 Partial	—	—	21d	—	16.0 mo	2	—	1
Donafenib monotherapy Variant #01 Partial	—	—	28d	—	12.1 mo	2	—	1
Apatinib and Camrelizumab Variant #01 Partial	—	—	14d	5.6 mo	23.0 mo	2	—	4
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	16.4 mo	2	—	1
Placebo Partial	—	—	—	—	4.2 mo	—	—	3

26 of 26 regimens shown